CDK4/6 inhibitors, Pfizer’s (PFE) Ibrance and Eli Lilly’s (LLY) Verzenio, have already made their mark in the breast cancer space. And now the market is waiting for CDK4/6 inhibitors to penetrate other oncology indications.
One such closely watched investigational compound is G1 Therapeutics’ (GTHX) trilaciclib, being developed as a first-in-class myelopreservation agent. Besides, the company also has other promising early-stage oncology assets such as CDK4/6 inhibitor, Lerociclib, and oral SERD (selective estrogen receptor degrader) G1T48, in its portfolio.
In the backdrop of the huge underserved market opportunity for trilaciclib and the near-term milestones,